ELTX Long Call Strategy

ELTX (Elicio Therapeutics, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating a diverse array of innovative immunotherapies for the treatment of various cancers and other diseases. The company's primary experimental drug, ELI-002, is an AMP therapeutic vaccine specifically formulated to target KRAS-driven cancers. Its development portfolio also encompasses ELI-004, an AMP-modified CpG adjuvant that forms part of ELI-002; ELI-007, a lymph node-targeted AMP-peptide vaccine addressing mutant BRAF-driven cancers; and ELI-008, a multivalent lymph node-targeted AMP-peptide vaccine for cancers expressing mutant TP53. Furthermore, Elicio is advancing ELI-005, a vaccine candidate for preventing COVID-19, and ELI-011 for hematological malignancies. Another program, ELI-012, is an mKRAS TCR T cell AMP-lifier designed for combined use with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company's operations are headquartered in Boston, Massachusetts.

ELTX (Elicio Therapeutics, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $58.3M, a beta of 1.88 versus the broader market, a 52-week range of 2.66-16, average daily share volume of 1.6M, a public-listing history dating back to 2021, approximately 33 full-time employees. These structural characteristics shape how ELTX stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 1.88 indicates ELTX has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.

What is a long call on ELTX?

A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration.

ELTX snapshot

As of August 14, 2026, spot at $3.11, ATM IV 322.90%, IV rank 66.11%, expected move 92.57%. The long call on ELTX below is built from the end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 35-day expiry.

Why this long call structure on ELTX specifically: ELTX IV at 322.90% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 92.57% (roughly $2.88 on the underlying). The 35-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated ELTX expiries trade a higher absolute premium for lower per-day decay. Position sizing on ELTX should anchor to the underlying notional of $3.11 per share and to the trader's directional view on ELTX stock.

ELTX long call setup

The ELTX long call below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With ELTX at $3.11 on that close, the first option leg uses a $3.11 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed ELTX chain at a 35-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 ELTX shares for the stock leg in covered calls and collars).

ActionTypeStrike / BasisPremium (est)
Buy 1Call$3.11N/A

ELTX long call risk and reward

Net Premium / Debit
N/A
Max Profit (per contract)
Unbounded
Max Loss (per contract)
Unbounded
Breakeven(s)
None on modeled curve
Risk / Reward Ratio
N/A

Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium.

ELTX long call payoff curve

Modeled P&L at expiration across a range of underlying prices for the long call on ELTX. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

When traders use long call on ELTX

Long calls on ELTX express a bullish thesis with defined risk; traders use them ahead of ELTX catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.

ELTX thesis for this long call

The market-implied 1-standard-deviation range for ELTX extends from approximately $0.23 on the downside to $5.99 on the upside. A ELTX long call expresses a directional view that the underlying closes above the strike plus premium at expiration, ideally with implied volatility holding or expanding to preserve extrinsic value through the hold period. Current ELTX IV rank near 66.11% is mid-range against its 1-year distribution, so the IV signal is neutral; the long call thesis on ELTX should anchor more to the directional view and the expected-move geometry. As a Healthcare name, ELTX options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to ELTX-specific events.

ELTX long call positions are structurally bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. ELTX positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move ELTX alongside the broader basket even when ELTX-specific fundamentals are unchanged. Long-premium structures like a long call on ELTX are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current ELTX chain quotes before placing a trade.

Frequently asked questions

What is a long call on ELTX?
A long call on ELTX is the long call strategy applied to ELTX (stock). The strategy is structurally bullish: A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration. With ELTX stock at $3.11 on the most recent close, the strikes shown on this page are snapped to the nearest listed ELTX chain strike and the premiums come straight from that session's bid/ask midpoint.
How are ELTX long call max profit and max loss calculated?
Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium. For the ELTX long call priced from the end-of-day chain at a 30-day expiry (ATM IV 322.90%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a ELTX long call?
The breakeven for the ELTX long call priced on this page is no defined breakeven on the modeled curve at expiration, derived from the end-of-day chain's premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The ELTX market-implied 1-standard-deviation expected move in the same options snapshot is approximately 92.57%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a long call on ELTX?
Long calls on ELTX express a bullish thesis with defined risk; traders use them ahead of ELTX catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
How does current ELTX implied volatility affect this long call?
ELTX ATM IV is at 322.90% with IV rank near 66.11%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.

Related ELTX analysis